PMC10359678_01
Timeline for the patient.
cro-2023-0016-0001-530547_F01.jpg
PMC10359678_01_cro-2023-0016-0001-530547_F01.jpg
F1
Thereafter, the patient was treated with an LH-RH agonist and enzalutamide; however, progression occurred on both (Fig. 1).
The dynamics of serum concentrations of cabazitaxel (CBZ) and clarithromycin (CAM). The horizontal axis shows the day the patient was first admitted was set as day 0. The vertical axis shows CBZ or CAM concentrations. White dots ( ) and black dots ( ) are shown for CBZ and CAM, respectively. LLD, limit of lower detection.
cro-2023-0016-0001-530547_F02.jpg
PMC10359678_01_cro-2023-0016-0001-530547_F02.jpg
F2
Liquid chromatography with tandem mass spectrometry revealed cabazitaxel and clarithromycin concentrations of 1.0 ng/mL and 69.7 ng/mL, respectively, on day 0 and 1.2 ng/mL and below the limit of lower detection (<20 ng/mL) on day 28 (Fig. 2).